Show Summary Details
Page of

HIV-1 Resistance to Antiretroviral Drugs 

HIV-1 Resistance to Antiretroviral Drugs
HIV-1 Resistance to Antiretroviral Drugs

Ye Thu

and Naiel Nassar

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 27 September 2020

Numerous epidemiologic studies of antiretroviral resistance in both treatment-experienced and treatment-naive individuals have been performed in the potent combination antiretroviral therapy (ART) era. The development of antiretroviral resistance depends on previous antiretroviral exposure, compliance with the medication, and availability of a fully active antiretroviral regimen for the individual patient. The previous exposure to ART medications plays significant role in developing drug resistance, especially in patients who are noncompliant with medications. Drug resistance testing should be done in the setting of treatment failure because it can help achieve better virologic response. There is extensive cross-resistance with first-generation non-nucleoside reverse transcriptase inhibitors and first-generation integrase strand inhibitors.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.